Clinical Study

The Effects of Helicobacter pylori Eradication on Proteinuria in Patients with Primary Glomerulonephritis

Table 2

Clinical and laboratory features of the patients before and after H. pylori eradication therapy.

MN group ( )IgAN group ( )FSGS group ( ) value

Male/female13/64/63/1NS
Age (years) NS
BMI (kg/m2) NS
Before therapy
 Systolic BP (mmHg) NS
 Diastolic BP (mmHg) NS
 Hemoglobin (g/dL) NS
 Glucose (mg/dL) NS
 Creatinine (mg/dL) 0.011
 T. protein NS
 Albumin (g/dL) NS
 Proteinuria (Up/C) (g/day) NS
 GFR (mL/min) NS
 T. cholesterol (mg/dL) NS
 Triglyceride (mg/dL) NS
 hs-CRP NS
After therapy
 Systolic BP (mmHg) NS
 Diastolic BP (mmHg) NS
 Hemoglobin (mg/dL) NS
 Creatinine (mg/dL) 0.005
 T. protein (g/dL) NS
 Albumin (g/dL) NS
 Proteinuria (g/day) NS
 GFR (mL/min) NS

AMN: membranous nephropathy, IgAN: IgA nephropathy, FSGS: focal segmental glomerulosclerosis, NS: not significant, GFR: glomerular filtration rate.